Edition:
United States

Genomic Health Inc (GHDX.OQ)

GHDX.OQ on NASDAQ Stock Exchange Global Select Market

57.34USD
20 Jul 2018
Change (% chg)

$-0.97 (-1.66%)
Prev Close
$58.31
Open
$58.25
Day's High
$58.36
Day's Low
$56.27
Volume
117,061
Avg. Vol
88,148
52-wk High
$58.83
52-wk Low
$26.54

Select another date:

Mon, May 21 2018

BRIEF-New Data Reinforce Positive Impact Of The Oncotype Dx Genomic Prostate Score Test In Guiding Treatment Decisions

* NEW DATA REINFORCE POSITIVE IMPACT OF THE ONCOTYPE DX® GENOMIC PROSTATE SCORE™ TEST IN GUIDING TREATMENT DECISIONS Source text for Eikon: Further company coverage:

BRIEF-Genomic Health Q1 Loss Per Share $0.11

* GENOMIC HEALTH ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND REPORTS RECENT BUSINESS PROGRESS

BRIEF-Tailorx Results Aid In Assessing The Effect Of Chemotherapy In Women With Early-Stage Breast Cancer And Oncotype Dx Breast Recurrence Score Results Of 11 To 25

* LANDMARK TAILORX RESULTS AID IN ASSESSING THE EFFECT OF CHEMOTHERAPY IN WOMEN WITH EARLY-STAGE BREAST CANCER AND ONCOTYPE DX BREAST RECURRENCE SCORE® RESULTS OF 11 TO 25

BRIEF-Genomic Health Reports Q4 Earnings Per Share $0.05

* GENOMIC HEALTH ANNOUNCES 2017 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS, PROVIDES 2018 FINANCIAL OUTLOOK

BRIEF-Genomic Health Reports Q4 Earnings Per Share $0.05

* GENOMIC HEALTH ANNOUNCES 2017 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS, PROVIDES 2018 FINANCIAL OUTLOOK

BRIEF-Genomic Health Expands Offering To Prostate Cancer Patients With Launch Of Oncotype DX AR-V7 Nucleus Detect Test To Predict Treatment Response In Metastatic Disease

* GENOMIC HEALTH EXPANDS OFFERING TO PROSTATE CANCER PATIENTS WITH LAUNCH OF ONCOTYPE DX® AR-V7 NUCLEUS DETECT™ TEST TO PREDICT TREATMENT RESPONSE IN METASTATIC DISEASE Source text for Eikon: Further company coverage:

BRIEF-Genomic Health - Oncotype DX Genomic Prostate Score™ Test Increases Use Of Active Surveillance

* ONCOTYPE DX® GENOMIC PROSTATE SCORE™ TEST INCREASES USE OF ACTIVE SURVEILLANCE BY 30 PERCENT IN LOW-RISK PATIENTS, RESULTING IN GREATER ADHERENCE TO GUIDELINE-BASED CARE Source text for Eikon: Further company coverage:

Select another date: